Next Article in Journal
Magnesium-Molybate Compounds as Matrix for 99Mo/99mTc Generators
Next Article in Special Issue
Mitochondrial Dysfunction and Oxidative Stress in Asthma: Implications for Mitochondria-Targeted Antioxidant Therapeutics
Previous Article in Journal
Fentanyl and Spiradoline Interactions in a Place-Conditioning Black-White Shuttle-Box
Open AccessArticle

L-Arginine Supplementation and Metabolism in Asthma

Pulmonary and Critical Care Medicine, University of California Davis, 451 Health Sciences Drive, GBSF, Rm. 6517, Davis, CA 95616, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2011, 4(1), 187-201; https://doi.org/10.3390/ph4010187
Received: 4 November 2010 / Revised: 3 January 2011 / Accepted: 10 January 2011 / Published: 12 January 2011
(This article belongs to the Special Issue Genes, Mechanisms and Drugs for Asthma)
L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebo-controlled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10−3 vs. 1.1 ± 0.2 × 10−3 µmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 µmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10−1 vs. 2.6 ± 0.6 × 10−1 µmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study. View Full-Text
Keywords: asthma; L-arginine; nitric oxide; arginase; ADMA asthma; L-arginine; nitric oxide; arginase; ADMA
MDPI and ACS Style

Kenyon, N.J.; Last, M.; Bratt, J.M.; Kwan, V.W.; O’Roark, E.; Linderholm, A. L-Arginine Supplementation and Metabolism in Asthma. Pharmaceuticals 2011, 4, 187-201.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop